Dwindling supplies of Ozempic are fuelling an “exploding” black market for the drug across Australia, as the medical industry is forced to assess which patients need the popular medication the most.
Novo Nordisk executive Camilla Sylvest says Australia generally has a relatively high prevalence of obesity compared with many other countries. Asked about the potential size of the Australian ...
Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...
Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...
Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...
Novo Nordisk's anti-TFPI antibody concizumab has ... Alhemo – is already approved in other markets, including Japan, Australia, and Switzerland, but was rejected by the FDA last year with ...
Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won't be selling it for much longer. Hims & Hers Health Inc.'s stock plunged last week when the ...
(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback